187 related articles for article (PubMed ID: 15695401)
21. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.
Fischer SM; Conti CJ; Viner J; Aldaz CM; Lubet RA
Carcinogenesis; 2003 May; 24(5):945-52. PubMed ID: 12771040
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
23. Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice.
Afaq F; Saleem M; Krueger CG; Reed JD; Mukhtar H
Int J Cancer; 2005 Jan; 113(3):423-33. PubMed ID: 15455341
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.
Arumugam A; Weng Z; Talwelkar SS; Chaudhary SC; Kopelovich L; Elmets CA; Afaq F; Athar M
PLoS One; 2013; 8(11):e80076. PubMed ID: 24260338
[TBL] [Abstract][Full Text] [Related]
25. Tip60 protein isoforms and altered function in skin and tumors that overexpress ornithine decarboxylase.
Hobbs CA; Wei G; DeFeo K; Paul B; Hayes CS; Gilmour SK
Cancer Res; 2006 Aug; 66(16):8116-22. PubMed ID: 16912189
[TBL] [Abstract][Full Text] [Related]
26. p44/42 mitogen-activated protein kinase is involved in the expression of ornithine decarboxylase in leukaemia L1210 cells.
Flamigni F; Facchini A; Capanni C; Stefanelli C; Tantini B; Caldarera CM
Biochem J; 1999 Jul; 341 ( Pt 2)(Pt 2):363-9. PubMed ID: 10393094
[TBL] [Abstract][Full Text] [Related]
27. Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors.
Chiou YS; Sang S; Cheng KH; Ho CT; Wang YJ; Pan MH
Carcinogenesis; 2013 Jun; 34(6):1315-22. PubMed ID: 23385063
[TBL] [Abstract][Full Text] [Related]
28. Modulation of chrysarobin skin tumor promotion.
DiGiovanni J; Kruszewski FH; Chenicek KJ
Carcinogenesis; 1988 Aug; 9(8):1445-50. PubMed ID: 3135955
[TBL] [Abstract][Full Text] [Related]
29. Effect of elevated levels of ornithine decarboxylase on cell cycle progression in skin.
Gilmour SK; Birchler M; Smith MK; Rayca K; Mostochuk J
Cell Growth Differ; 1999 Nov; 10(11):739-48. PubMed ID: 10593650
[TBL] [Abstract][Full Text] [Related]
30. Conversion of C57Bl/6 mice from a tumor promotion-resistant to a -sensitive phenotype by enhanced ornithine decarboxylase expression.
Guo Y; Zhao J; Sawicki J; Peralta Soler A; O'Brien TG
Mol Carcinog; 1999 Sep; 26(1):32-6. PubMed ID: 10487519
[TBL] [Abstract][Full Text] [Related]
31. Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice.
Fischer SM; Lee M; Lubet RA
Carcinogenesis; 2001 Jan; 22(1):83-8. PubMed ID: 11159745
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of tumor promoter 12-O-tetradecanoylphorbol-13-acetate-induced synthesis of epidermal ornithine decarboxylase messenger RNA and diacylglycerol-promoted mouse skin tumor formation by retinoic acid.
Verma AK
Cancer Res; 1988 Apr; 48(8):2168-73. PubMed ID: 3349487
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW
Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253
[TBL] [Abstract][Full Text] [Related]
34. Quinone methide mediates in vitro induction of ornithine decarboxylase by the tumor promoter butylated hydroxytoluene hydroperoxide.
Guyton KZ; Dolan PM; Kensler TW
Carcinogenesis; 1994 May; 15(5):817-21. PubMed ID: 8200081
[TBL] [Abstract][Full Text] [Related]
35. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
36. Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice.
Saleem M; Afaq F; Adhami VM; Mukhtar H
Oncogene; 2004 Jul; 23(30):5203-14. PubMed ID: 15122342
[TBL] [Abstract][Full Text] [Related]
37. Effects of timing of administration and dose of difluoromethylornithine on rat colonic carcinogenesis.
Luk GD; Zhang SZ; Hamilton SR
J Natl Cancer Inst; 1989 Mar; 81(6):421-7. PubMed ID: 2493096
[TBL] [Abstract][Full Text] [Related]
38. Deregulation of polyamine biosynthesis alters intrinsic histone acetyltransferase and deacetylase activities in murine skin and tumors.
Hobbs CA; Paul BA; Gilmour SK
Cancer Res; 2002 Jan; 62(1):67-74. PubMed ID: 11782361
[TBL] [Abstract][Full Text] [Related]
39. Role of ornithine decarboxylase in epidermal tumorigenesis.
Clifford A; Morgan D; Yuspa SH; Soler AP; Gilmour S
Cancer Res; 1995 Apr; 55(8):1680-6. PubMed ID: 7712475
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
